CLINICAL TRIAL SUMMARY

MDACC Study No:2012-1047 (clinicaltrials.gov NCT No: NCT01892371)
Title:Phase I/II Study of the Combination of Quizartinib (AC220) with 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Principal Investigator:Jorge Cortes
Treatment Agent:5-Azacytidine; AC220; Cytarabine
Study Status:Open
Study Description:The goal of the Phase 1 part of this clinical research study is to find the
highest tolerable dose of AC220 (quizartinib) that can be given with either
5-azacitidine (azacitidine) or cytarabine to patients with AML or MDS.

The goal of the Phase 2 part of the study is to learn if quizartinib with
either azacitidine or cytarabine can help to control AML or MDS. The safety of
these combinations will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:5-Azacytidine
AC220
Cytarabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Ambit Biosciences
Celgene
Leukemia SPORE
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
Dept:Leukemia
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults